Comparative Pharmacology
Head-to-head clinical analysis: TATUM T versus WOLFINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TATUM T versus WOLFINA.
TATUM-T vs WOLFINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TATUM-T is a combination of ethynodiol diacetate, a progestin, and ethinyl estradiol, an estrogen. It suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation. Additionally, it increases viscosity of cervical mucus, impeding sperm penetration, and alters the endometrium to reduce implantation likelihood.
Not specified in available data; likely unapproved or investigational drug.
One tablet (ethinyl estradiol 0.035 mg / norgestimate 0.250 mg) orally once daily for 21 days, followed by 7 days of placebo.
Initial: 50 mg orally twice daily. Titrate to 100 mg twice daily after 2 weeks based on tolerability.
None Documented
None Documented
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours in creatinine clearance <30 mL/min) requiring dose adjustment
Terminal elimination half-life is 12-18 hours in healthy adults; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Primarily renal (65-70% as unchanged drug); biliary/fecal (20-25%); minor metabolism to inactive glucuronide conjugates (<10%)
Primarily renal (70% unchanged), with 20% biliary/fecal and 10% metabolic degradation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive